Inclusion Criteria:

- Age over 18 years

- Patients with HCC, NSCLC, RCC or CRC treated with an approved antiangiogenic drug
(bevacizumab, sorafenib, sunitinib)*

- Patients with at least one measurable lesion. Lesions must be measurable by CT-scan
or MRI (Magnetic resonance imaging) according to Response Evaluation Criteria in
Solid Tumours (RECIST)

Exclusion Criteria:

- Pregnant or breast-feeding patients. Women of childbearing potential must have a
negative pregnancy test performed within 7 days of the start of treatment. Both men
and women enrolled in this trial must use adequate birth control measures during the
course of the trial. The definition of effective contraception will be based on the
judgment of the principal investigator or a designated associate.

- Substance abuse, medical, psychological or social conditions that may interfere with
the patient's participation in the study or evaluation of the study results

- Known or suspected allergy to the investigational agent or any agent given in
association with this trial -_> allergy

- MRI contraindications: implants (pacemaker)